|Bid||160.50 x 1000|
|Ask||160.75 x 1400|
|Day's Range||159.11 - 161.41|
|52 Week Range||109.16 - 161.95|
|Beta (5Y Monthly)||0.70|
|PE Ratio (TTM)||25.20|
|Forward Dividend & Yield||4.04 (2.51%)|
|Ex-Dividend Date||Feb 22, 2021|
|1y Target Est||N/A|
President-elect Joe Biden released a $1.9 trillion COVID-19 response plan on Thursday evening, setting goals for his first 100 days in office, including a call for 100 million vaccinations by then.
The following is a roundup of some of the latest scientific studies on the novel coronavirus and efforts to find treatments and vaccines for COVID-19, the illness caused by the virus. An experimental COVID-19 vaccine from Johnson & Johnson produced protective antibodies against the novel coronavirus in 90% of 805 volunteers by 29 days, and that increased to 100% by day 57, according to data from an ongoing mid-stage study. To be approved by regulators, the J&J vaccine must show efficacy as reflected by a lower risk of infections and severe disease in study participants who receive it compared to those who do not.
Novavax is making a play for a coronavirus vaccine, vs. giants like Pfizer, and other rivals like Moderna. But NVAX stock has been volatile. Is Novavax stock a buy right now?